Table 2.
Summary of studies included in the meta-analyses and odds ratio.
| Publication | Sample size | Sample characteristics | Age (years)a | Agent/comparisonb | Duration |
|---|---|---|---|---|---|
| Meta analyses | |||||
| Blouin et al. (2008) | 38 (18 SGA, 20 controls) | First psychoses, non-schizophrenic patients | 30.5 ± 7.9 SGA | Clozapine, olanzapine, risperidone, quetiapine & ziprasidone/controls | >3 months |
| 29.5 ± 6.7 reference | |||||
| Khazaal et al. (2009) | 37 (22 SGAs, 15 controls) | Schizophrenia & schizoaffective disorders | 30 ± 8.3 | Olanzapine, clozapine, risperidone & quetiapine/controls | NR |
| Sentissi et al. (2009) | 153 (93 SGA, 27 FGA, 33 controls) | Schizophrenic | 33.1 ± 8.7 | Clozapine, olanzapine, amisulpride, risperidone & aripiprazole/controls | >3 months |
| Odds ratio | |||||
| McCracken et al. (2002) | 101 (49 Risperidone, 51 Placebo) | Autism disorder | 8.8 ± 2.7 | 1.8 mg/d risperidone/placebo | 24 |
| Snyder et al. (2002) | 110 (53 Risperidone, 57 placebo) | Conduct and disruptive behaviour disorder | 5–12 | 0.98 mg/day risperidone/placebo | 7 |
| Guardia et al. (2004) | 60 (29 Olanzapine, 31 Placebo) | Alcohol-dependence disorder | 18–60 | 7.54 mg/d olanzapine/placebo | 12 |
| Aman et al. (2005) | 101 (49 Risperidone, 52 placebo) | Autism disorder | 8.8 ± 2.7 | <20–44.9 kg: 0.5 mg titrated to 2.5 mg/day | 26 |
| >45 kg: 0.5 mg titrated to 3.5 mg/day risperidone/placebo | |||||
| Roerig et al. (2005) | 48 (16 olanzapine, 16 Risperidone/16 placebo) | Healthy | 18–60 | 8.75 mg/d olanzapine & 2.875 mg/d risperidone/placebo | 2 |
| Litten et al. (2012) | 218 (113 placebo 105 Quetiapine) | Alcohol-dependence disorder | 18–64 | Target dose of 400 mg/d quetiapine/placebo | 17 |
| Srivastava et al. (2012) | 50 (25 olanzapine & 25 placebo) | Bipolar disorder | 40.8 ± 11.5 | Olanzapine/placebod | 1 |
| Black et al. (2014) | 111 (33 low-dose, 33 moderate-dose, 29 placebo) | Borderline personality disorder | 18–45 | 150–300 mg/d quetiapine/placebo | 8 |
Shaded rows indicate the inclusion of children and adolescents. All studies included in the odds ratio calculation are randomized controlled trials. Studies included in the eating behaviour meta-analyses are cross-sectional studies. NR: Not reported.
a
Age range in years was reported when mean ± standard deviation was not available.
b
Mean dose of the treatment agent was reported. c Represents the duration of intervention in weeks.
d
Drug dose was not mentioned.